Generative models for synthetic data generation: application to pharmacokinetic/pharmacodynamic data

2024-8-27

A review of the physiological effects of microgravity and innovative formulation for space travelers

2024-8-20

Visual predictive check of longitudinal models and dropout

2024-8-18

General quasi-equilibrium multivalent binding model to study diverse and complex drug-receptor interactions of biologics

2024-8-17

Time Scale Calculus: a new approach to multi-dose pharmacokinetic modeling

2024-7-25

A quantitative modeling framework to understand the physiology of the hypothalamic-pituitary-adrenal axis and interaction with cortisol replacement therapy

2024-7-8

Likelihood comparisons in bounded outcome score analysis must be internally consistent

2024-7-5

Mixed effect estimation in deep compartment models: Variational methods outperform first-order approximations

2024-7-4

pyDarwin machine learning algorithms application and comparison in nonlinear mixed-effect model selection and optimization

2024-6-28

An asymptotic description of a basic FcRn-regulated clearance mechanism and its implications for PBPK modelling of large antibodies

2024-6-24

Advancing cancer drug development with mechanistic mathematical modeling: bridging the gap between theory and practice

2024-6-21

Virtual clinical trials via a QSP immuno-oncology model to simulate the response to a conditionally activated PD-L1 targeting antibody in NSCLC

2024-6-10

Generation of realistic virtual adult populations using a model-based copula approach

2024-6-6

Correction: Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson’s disease

2024-5-30

Authors’ response to letter to editor

2024-5-27

ChatGPT and Gemini large language models for pharmacometrics with NONMEM: comment

2024-5-25

Correction: Oral docetaxel plus encequidar – a pharmacokinetic model and evaluation against IV docetaxel

2024-5-14

A quantitative systems pharmacology model of plasma kallikrein-kinin system dysregulation in hereditary angioedema

2024-5-11

Note on importance of correct stoichiometric assumptions for modeling of monoclonal antibodies

2024-5-3

Translational two-pore PBPK model to characterize whole-body disposition of different-size endogenous and exogenous proteins

2024-5-1

Evaluation of ChatGPT and Gemini large language models for pharmacometrics with NONMEM

2024-4-24

Target-mediated drug disposition model for drugs with N > 2 binding sites that bind to a target with one binding site

2024-4-19

A systematic evaluation of population pharmacokinetic models for polymyxin B in patients with liver and/or kidney dysfunction

2024-4-16

Five multivariate Duchenne muscular dystrophy progression models bridging six-minute walk distance and MRI relaxometry of leg muscles

2024-4-12

Impact of covariate model building methods on their clinical relevance evaluation in population pharmacokinetic analyses: comparison of the full model, stepwise covariate model (SCM) and SCM+ approaches

2024-4-9

Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson’s disease

2024-4-5

Docetaxel, cyclophosphamide, and epirubicin: application of PBPK modeling to gain new insights for drug-drug interactions

2024-3-30

Longitudinal modeling of efficacy response in patients with lupus nephritis receiving belimumab

2024-3-29

On inductive biases for the robust and interpretable prediction of drug concentrations using deep compartment models

2024-3-26

Maximum a posteriori Bayesian methods out-perform non-compartmental analysis for busulfan precision dosing

2024-3-23

Oral docetaxel plus encequidar – A pharmacokinetic model and evaluation against IV docetaxel

2024-3-19

Predicting efficacy assessment of combined treatment of radiotherapy and nivolumab for NSCLC patients through virtual clinical trials using QSP modeling

2024-3-17

An industry perspective on current QSP trends in drug development

2024-3-5

Employing zero-inflated beta distribution in an exposure-response analysis of TYK2/JAK1 inhibitor brepocitinib in patients with plaque psoriasis

2024-3-3

Fourteenth American Conference on Pharmacometrics (ACoP14) – Innovation and Diversity: Redefining Pharmacometrics

2024-2-28

Subgroup identification-based model selection to improve the predictive performance of individualized dosing

2024-2-24

A minimal physiologically based pharmacokinetic model to study the combined effect of antibody size, charge, and binding affinity to FcRn/antigen on antibody pharmacokinetics

2024-2-24

Population pharmacokinetics of the dual endothelin receptor antagonist aprocitentan in subjects with or without essential or resistant hypertension

2024-2-8

A population pharmacokinetics model of balovaptan to support dose selection in adult and pediatric populations

2024-2-3

Thoughts on plagiarism and the case against Claudine Gay

2024-2-1

Correction: External control arms for rare diseases: building a body of supporting evidence

2024-1-19

How drug onset rate and duration of action affect drug forgiveness

2024-1-10

Semi-mechanistic modeling of resistance development to β-lactam and β-lactamase-inhibitor combinations

2023-11-26

Comparison of monoclonal antibody disposition predictions using different physiologically based pharmacokinetic modelling platforms

2023-11-12

Evaluation of prompt engineering strategies for pharmacokinetic data analysis with the ChatGPT large language model

2023-11-11

Expansion of platform physiologically-based pharmacokinetic model for monoclonal antibodies towards different preclinical species: cats, sheep, and dogs

2023-11-10

Characterization of anti-drug antibody dynamics using a bivariate mixed hidden-markov model by nonlinear-mixed effects approach

2023-11-9

Explaining in-vitro to in-vivo efficacy correlations in oncology pre-clinical development via a semi-mechanistic mathematical model

2023-11-6

Rare oncology therapeutics: review of clinical pharmacology package of drug approvals (2019–2023) by US FDA, best practices and recommendations

2023-11-4

Learning pharmacometric covariate model structures with symbolic regression networks

2023-10-21